Fri, May 4, 2018
Thu, May 3, 2018
Wed, May 2, 2018
Tue, May 1, 2018
Mon, April 30, 2018
Fri, April 27, 2018
Thu, April 26, 2018
Wed, April 25, 2018
Tue, April 24, 2018

Matthew Harrison Maintained (BMRN) at Buy with Increased Target to $113 on, Apr 30th, 2018


  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. th-increased-target-to-113-on-apr-30th-2018.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matthew Harrison of Morgan Stanley, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $112 to $113 on, Apr 30th, 2018.

Matthew has made no other calls on BMRN in the last 4 months.



There are 6 other peers that have a rating on BMRN. Out of the 6 peers that are also analyzing BMRN, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with Matthew


  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $116 on, Friday, March 2nd, 2018
  • Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $124 on, Friday, February 23rd, 2018
  • Joseph Schwartz of "Leerink Swann" Maintained at Buy with Decreased Target to $132 on, Friday, February 23rd, 2018
  • M. Ian Somaiya of "BMO Capital" Maintained at Buy with Increased Target to $125 on, Friday, February 23rd, 2018
  • Stephen Willey of "Stifel" Maintained at Strong Buy with Decreased Target to $102 on, Friday, February 23rd, 2018
  • Cory Kasimov of "JP Morgan" Maintained at Buy with Decreased Target to $129 on, Wednesday, January 24th, 2018

Publication Contributing Sources